What is Zacks Research's Forecast for PCRX Q4 Earnings?

Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Zacks Research lowered their Q4 2026 earnings estimates for shares of Pacira BioSciences in a report issued on Thursday, July 17th. Zacks Research analyst R. Department now anticipates that the company will earn $0.65 per share for the quarter, down from their prior forecast of $0.66. The consensus estimate for Pacira BioSciences' current full-year earnings is $2.41 per share. Zacks Research also issued estimates for Pacira BioSciences' Q2 2027 earnings at $0.61 EPS.

A number of other research firms also recently issued reports on PCRX. Needham & Company LLC lowered their price objective on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Wall Street Zen upgraded shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Finally, HC Wainwright lifted their price objective on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $26.44.

Pacira BioSciences Trading Up 2.7%

Shares of NASDAQ:PCRX traded up $0.58 during mid-day trading on Monday, reaching $22.17. The stock had a trading volume of 872,167 shares, compared to its average volume of 886,130. The firm has a market cap of $1.03 billion, a PE ratio of -9.72 and a beta of 0.48. The firm has a 50 day simple moving average of $24.54 and a two-hundred day simple moving average of $24.44. The company has a current ratio of 2.41, a quick ratio of 1.99 and a debt-to-equity ratio of 0.48. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $27.64.

Hedge Funds Weigh In On Pacira BioSciences

A number of large investors have recently modified their holdings of the company. Sterling Capital Management LLC grew its position in shares of Pacira BioSciences by 779.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock worth $26,000 after buying an additional 1,208 shares during the last quarter. Ancora Advisors LLC bought a new stake in shares of Pacira BioSciences in the 4th quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Pacira BioSciences in the 1st quarter worth approximately $51,000. Brooklyn Investment Group grew its position in shares of Pacira BioSciences by 372.2% in the 1st quarter. Brooklyn Investment Group now owns 2,238 shares of the company's stock worth $56,000 after buying an additional 1,764 shares during the last quarter. Finally, US Bancorp DE grew its position in shares of Pacira BioSciences by 31.0% in the 1st quarter. US Bancorp DE now owns 2,270 shares of the company's stock worth $56,000 after buying an additional 537 shares during the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Pacira BioSciences news, SVP Lauren Riker sold 5,578 shares of the firm's stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total value of $146,199.38. Following the completion of the transaction, the senior vice president owned 59,564 shares in the company, valued at $1,561,172.44. This trade represents a 8.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 6.40% of the stock is currently owned by corporate insiders.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.